
 
 
 
 
 
 
 
 
   
 1. An isolated DNA or RNA nucleic acid molecule comprising a nucleotide Ssequence selected from the group consisting of O 5 a fragment of SEQ ID NO: 1,3, 5, 11, 13, 15, 17, 19, 21 or 23 wherein the encoded polypeptide of the fragment maintains biological and immunological activity of a DmGPCR; 00 a sequence having at least 95% sequence identity to a fragment of SEQ ID 00 NO:1, 3, 5, 9, 11, 13, 15, 17, 19, 21, or 23 wherein the encoded polypeptide of C 10 the fragment maintains biological and immunological activity of a DmGPCR; a sequence that encodes a polypeptide comprising a fragment of SEQ ID NO: 2, 4, 6, 12, 14, 16, 18, 20, 22 or 24 wherein the fragment maintains biological and immunological activity of a DmGPCR; and a sequence that encodes an amino acid sequence having at least sequence identity to a fragment of SEQ ID NO: 2, 4, 6, 12, 14, 16, 18, 20, 22 or 24 wherein the fragment maintains biological and immunological activity of a DmGPCR; said nucleic acid molecule encoding at least a portion of DmGPCR; wherein the nucleic acid comprises no more that 1803 nucleotides if the nucleotide sequence is SEQ ID NO:1; and wherein the nucleic acid comprises no more than 1628 nucleotides if the nucleotide sequence is SEQ ID NO:17. 
 
     
 2. The nucleic acid molecule of claim 1 wherein said nucleotide sequence comprises a fragment of SEQ ID NO:1, 3, 5, 11, 13, 15, 17, 19, 21 or 23. 
 
     
 3. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to a fragment of SEQ ID NO:1, 3, 5, 11, 13, 15, 17, 19, 21 or 23, a complement of said nucleic acid molecule encoding at least a portion of a DmGPCR that maintains biological and immunological activity of a DmGPCR. 
 
     
 4. The nucleic acid molecule of claim 3 wherein said molecule is an antisense oligonucleotide directed to a fragment of SEQ ID NO: 1, 3, 5, 11, 13, 15, 17, 19, 21 or 
 
     
 23. The nucleic acid molecule of claim 4 wherein said oligonucleotide is directed to a regulatory region of SEQ ID NO:1, 3, 5, 11, 13, 15, 17, 19, 21 or 23. 'W Mak Wickh an 725O32 0 lB_1 l doc 00 O O 6. An expression vector comprising a nucleic acid molecule of claim 1 or 3, wherein said nucleic acid molecule is operably connected to a promoter selected from Sthe group consisting of simian virus 40, mouse mammary tumor virus, long terminal Io 5 repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metalothionein; and wherein 00 the vector is a plasmid or viral particle. 00 C 10 7. An expression vector of claim 6 wherein said nucleic acid molecule comprises SSEQ ID NO: 1, 3, 5, 11, 13, 15, 17, 19, 21, or 23. 8. The vector of claim 6 wherein said vector is a viral particle selected from the group consisting of adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses. 9. A host cell transformed with a vector of claim 6, wherein said host cell is a bacterial cell, a yeast, an insect cell, or a mammalian cell. The transformed host cell of claim 9 wherein the host cell is a mammalian cell selected from the group consisting of Chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human 293 cells, and murine 3T3 fibroblasts. 11. A method of producing a polypeptide comprising a fragment of SEQ ID NO: 2, 4, 6, 12, 14, 16, 18, 20, 22 or 24 wherein the fragment maintains biological and immunological activity of a DmGPCR, comprising the steps of: introducing a recombinant expression vector of claim 6 into a compatible host cell; growing said host cell under conditions for expression of said polypeptide; and recovering said polypeptide, wherein said polypeptide is recovered by purifying the culture medium without lysing said host cell or wherein said host cell is lysed and said polypeptide is recovered from the lysate of said host cell. WXM..,k WckJ ,Al\700000-7999 \762E9\762891-23032008 clinis do, 0 12. A composition comprising a nucleic acid molecule of claim 1 or 3 and an Sacceptable carrier or diluent. G 13. A composition comprising a recombinant expression vector of claim 6 and an 0 5 acceptable carrier or diluent. 14. An isolated polypeptide encoded by a nucleic acid molecule of claim 1, 00 wherein the polypeptide maintains biological and immunological activity of a 00 DmGPCR. Ni The polypeptide of claim 14 wherein said polypeptide comprises a fragment of SEQ ID NO:2, 4, 6, 12, 14, 16, 18, 20, 22 or 24. 16. An isolated polypeptide comprising an amino acid sequence having at least 95% sequence identity to a fragment of SEQ ID NO:2, 4, 6,12, 14, 16, 18, 20, 22 or 24, wherein the fragment maintains biological and immunological activity of a DmGPCR. 17. The polypeptide of claim 16 wherein said sequence which has at least sequence identity to a fragment of SEQ ID NO:2, 4, 6, 12, 14, 16, 18, 20, 22 or 24 comprises at least one conservative amino acid substitution compared to SEQ ID NO:2, 4, 6, 12, 14, 16, 18, 20, 22 or 24. 18. A composition comprising a polypeptide of claim 16 and an acceptable carrier or diluent. 19. An isolated antibody which is specific for an epitope on a polypeptide of claim 16. 20. The antibody of claim 19 wherein said antibody is a monoclonal antibody. 21. A composition comprising an antibody of claim 19 and an acceptable carrier or diluent. 22. A method of inducing an immune response in a mammal against a polypeptide of claim 16 comprising administering to said mammal an amount of said polypeptide sufficient to induce said immune response. W \lWiak WicLhani7\00 O 799 \762891\76291 25032008cIins do 00 O 23. A method for identifying a compound which binds a DmGPCR comprising the steps of: a) contacting the DmGPCR with a compound, wherein the DmGPCR is encoded by a polypeptide having at least 95% sequence identity to a fragment of SEQ ID NO:2, 4, 6, 12, 14, 16, 18, 20, 22, or 24, wherein the fragment maintains biological and immunological activity of a 00 DmGPCR; and 00 b) determining whether said compound binds DmGPCR. Ci  
 
     
 024. The method of claim 23 wherein said binding of said compound to DmGPCR is 0 determined by a protein binding assay is selected from the group consisting of a gel- shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwesern analysis, and ELISA. A method for identifying a compound which binds a nucleic acid molecule encoding DmGPCR comprising the steps of: a) contacting said nucleic acid molecule encoding DmGPCR with a compound, wherein the nucleic acid comprises a nucleotide sequence having at least 95% sequence identity to a fragment of SEQ ID NO:1, 3, 5, 11, 13, 15, 17, 19, 21 or 23; and b) determining whether said compound binds said nucleic acid molecule. 
 
     
 26. A method of identifying an animal homolog of DmGPCR comprising the steps; a) screening a nucleic acid database or a nucleic acid library of the animal with a nucleic acid molecule having a nucleotide sequence selected from the group consisting of a fragment of SEQ ID NO:1, 3, 5, 11, 13, 17, 19, 21, or 23, wherein the encoded polypeptide of the fragment maintains biological and immunological activity of a DmGPCR and b) determining whether a portion of said library or said database has at least 95% sequence identity to said a fragment of SEQ ID NO:1, 3, 7, 11, 13, 15, 17, 19, 21 or 23. 
 
     
 27. A nucleic acid molecule according to claim 1 or 3, substantially as hereinbefore described. W'ML 'Mak W. \.7,0ODOO 799997\62891\762R99 25032008 clrinls d. 
 
     
 28. An expression vector according to claim 6, substantially as hereinbefore described. 
 
     
 29. A method according to claim 11, 23, 25, or 26 substantially as hereinbefore described. WAKIik Wickl \700009-799"9 76289)\76 _925O320S 0lrin. do. 
 
   
 
 
 
 
 
 
 
 
